Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.

What Was Tested

Researchers studied VIP (Vasoactive Intestinal Peptide) in this randomized controlled trial publication.

This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.

This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.

Who Took Part

The study group was 19 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.

Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got VIP (Vasoactive Intestinal Peptide) and who got the comparison, which limits bias.

As a double-blind VIP (Vasoactive Intestinal Peptide) study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of VIP (Vasoactive Intestinal Peptide), giving a reference point.

More than one site took part, so the patients came from several places.

A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.

A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.

What Was Measured

Topics PubMed links to this paper include Administration, Inhalation, COVID-19 Drug Treatment, COVID-19, SARS-CoV-2 and Hospitalization.

Author keywords: Aviptadil and Lung injury.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of VIP (Vasoactive Intestinal Peptide) in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 16 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Medical principles and practice : international journal of the Kuwait University, Health Science Centre), a journal based in Switzerland.

More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.